Reduced Levels of Plasma Lipoxin A4 Are Associated with Post-Stroke Cognitive Impairment.
Reduced Levels of Plasma Lipoxin A4 Are Associated with Post-Stroke Cognitive Impairment.
复制标题
DOI：
10.3233/jad-201050
复制
发表时间：
2020-12
期刊：
影响因子：
--
通讯作者：
Xiuzhe Wang;Z. Miao;Xiaofen Xu;Marianne Schutlzberg;Yuwu Zhao
中科院分区：
文献类型：
--
作者：
Xiuzhe Wang;Z. Miao;Xiaofen Xu;Marianne Schutlzberg;Yuwu Zhao
背景专门化前体(SPM)是来源于n-3和n-6多不饱和脂肪酸的生物活性脂类。SPM促进炎症的消退，并在阿尔茨海默病中减少。目前尚不清楚SPM是否与卒中后认知功能障碍(PSCI)有关。目的探讨PSCI患者缺血性卒中急性期血浆SPM水平的变化。方法采用酶免疫法测定36例PSCI患者和33例卒中后非认知功能障碍(PSNCI)患者的血浆SPM水平。结果PSCI患者SPM脂氧素A4(LXA4)水平明显低于PSNCI患者。有趣的是，LXA4水平与简易精神状态检查分数呈正相关，但与美国国立卫生研究院中风量表分数无关。在其他SPM中未发现这种变化和相关性。结论PSCI患者在缺血性卒中急性期血浆LXA4水平降低，并与认知功能有关。
BACKGROUND Specialized pro-resolving mediators (SPMs) are bioactive lipids derived from n-3 and n-6 polyunsaturated fatty acids. SPMs promote resolution of inflammation and are reduced in Alzheimer's disease. It is unknown whether SPMs are associated with post-stroke cognitive impairment (PSCI). OBJECTIVE In the present report, we aimed to study the levels of SPMs in PSCI patients in the acute phase of ischemic stroke. METHODS Levels of SPMs in the plasma from 36 patients with PSCI and 33 patients with post-stroke non-cognitive impairment (PSNCI) were measured by enzyme immunoassay. RESULTS We found that levels of the SPM lipoxin A4 (LXA4) were significantly reduced in PSCI patients compared with PSNCI patients. Interestingly, the LXA4 levels were positively correlated with Mini-Mental State Examination scores, but not with the National Institutes of Health Stroke Scale scores. Such alteration and correlation were not found in any of the other SPMs analyzed, i.e., including resolvin D1, resolvin D2, resolvin E1, and maresin 1. CONCLUSION We conclude that the plasma levels of LXA4 were reduced in PSCI patents in the acute phase of ischemic stroke and were correlated to cognitive function.